



General description

Mercaptopurine is a purine antimetabolite antineoplastic agent used in treatment protocols for various leukaemias and lymphomas.

INN	Mercaptopurine
Medicine type	Chemical agent
EML status history	First added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2015 (TRS 994) for Lymphoid leukaemia, NOS Added in 2015 (TRS 994) for Acute myeloid leukaemia with recurrent genetic abnormalities Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
Therapeutic equivalent for	
Wikipedia	Mercaptopurine 
DrugBank	Mercaptopurine 

Recommendations

Section Cytotoxic medicines

Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, NOS

Acute myeloid leukaemia with recurrent genetic abnormalities

Unspecified malignant neoplasms of ill-defined or unspecified sites

